Rubius Therapeutics EBIT

Rubius Therapeutics's ebit stands at $-160M as of December 2022. That compares with $-190M in the prior-year period — up 19.8% year over year. That is below the Healthcare sector average of $22B. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Rubius Therapeutics reported $-160M in EBIT versus $-190M a year earlier — a 19.8% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

Rubius Therapeutics sits lower the Healthcare benchmark ($22B) with a EBIT of $-160M. That is roughly 100.7% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

That compares with $-190M in the prior-year period — up 19.8% year over year. Sustained growth in EBIT can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Rubius Therapeutics's EBIT evolved across reporting periods, while the comparison chart places RUBY next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.